P53 protein expression in non-Hodgkin's lymphoma. Comparative study with the wild type p53 induced proteins mdm2 and p21/wafl

Journal of Clinical Pathology - Clinical Molecular Pathology

Volumn 49, Issue 5, 1996, Pages

  Tzardi, M ^a   Kouvidou, Ch ^a   Panayiotides, I ^a   Stefanaki, K ^a   Rontogianni, D ^b   Zois, E ^b   Koutsoubi, K ^c   Eliopoulos, G ^a   Delides, G ^a   Kanavaros, P ^d  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c Venizelion Hospital of Heraklion   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Mdm2; Non hodgkin's lymphoma; P21; P53

Indexed keywords

PROTEIN P21; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0029797626     PISSN: 13552910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Levine A, Momand J, Finlay C. The p53 tumour suppressor gene. Nature 1992:351:453-6.
2. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
3. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, et al. P53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88:5413-17.
4. Villuendas R, Pins MA, Algara P, Sanchez-Beato M, Sanchez-Verde L, Martinez JC, et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 1993;82:3151-6.
5. Kocialkowski S, Pezzela F, Morrison H, Jones M, Laha S, Harris AL, et al. Mutations in the p53 gene are not limited to classic 'hot spots' and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br J Haemaiol 1995;89:55-60.
6. Barak Y, Oren M. Enhanced binding of a 95 kd protein to p53 in cells undergoing p53-mediated growth arrest. EMBOJ 1992;! 1:2115-21.
7. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
8. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-60.
9. Finlay CA. The mdm2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993;13:301-6.
10. Juven T, Barak Y, Zauberman A, George DL, Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 1993;8:3411-16.
11. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
12. Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB. Interactions between p53 and mdm2 in a mammalian cell cycle checkpoint pathway. Proc Nad Acad SciUSA 1994;91:2684-91.
13. El-Deiry WS, Tokino T, Velculesku VE, Levy DB, Parsons R, Trent JM, et al. Wafl, a potential mediator of p53 tumour suppression. Cell 1993;75:817-25.
14. Harper JW, Adam GY, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinase. Cell 1993;7S:805-16.
15. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is universal inhibitor of cyclin kinase. Nature 1993;366:701-4.
16. Gu Y, Turk CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20 k regulatory subunit. Nature 1993;366:707-10.
17. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature 1994;369:574-8.
18. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am JPajAo/1993;143:845-56.
19. Nakamura H, Said JW, Miller CW, Koeffler HP. Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas. Blood 1993; 82:920-6.
20. Martinez JC, Mateo MS, Sanchez-Beato M, Villuendas R, Orrade JL, Algara P, et al. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. J Pathol 1995;177:27-35.
21. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32:219-22.
22. Kanavaros P, Kouvidou Ch, Dai Y, Tzardi M, Datseris G, Darivianaki K, et al. MDM2 protein expression in nasopharyngeal carcinomas. Comparative study with p53 protein expression. J Clin Pathol: Mol Pathol 1995;48: M322-5.
23. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-18.
24. Reiferberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-9.
25. Sheikh MS, Shao ZM, Hussain A, Fontana JA. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993;53: 3226-8.
26. Bueso-Ramos CE, Yang Y, de Leon E, McCown P, Stass SA, Albitar M. The human MDM2 oncogene is overexpressed in leukemias. Blood 1993;82:2617-23.
27. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low grade lymphoma of B-cell origin. Blood 1994;9:3158-65.
28. Chilosi M, Doglioni C, Menestrina F, Montagna L, Rigo A, Lestani M, et al. Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood 1994;84:4295300.
29. Pezzella F, Morrison H, Jones M, Lane D, Harris AL, Mason DY. Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 1993;22:39-44.
30. Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Post-thymic T-cell lymphomas frequently overexpress p53 protein but infrequently exhibit gene mutations. Am J Pathol 1994;144:573-84.
31. Villuendas R, Pins MA, Orradre JL, Mollejo M, Algara P, Sanchez L, et al. P53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 1992;166:235-41.
32. Landers JE, Haines DS, Straus JF, George DL. Enhanced translation; a novel model of mdm2 oncogene overexpression identified in human tumour cells. Oncogene 1994;9: 2745-51.
33. Steinman RA, Huffman B, Iro A, Guillouf C, Liebermann DA, Houseini ME. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 1994;9:3389-96.
34. Sanchez-Beato M, Pins MA, Martinez-Montero JC, Garcia JF, Villuendas R, Garcia FJ, et al. Mdm2 and p21/wafl, wild type p53 induced proteins are regularly expressed by Reed-Sternberg cells in Hodgkin's disease. J Pathol (in press).